Dingdang Health Technology Group Ltd. reported to the Hong Kong Stock Exchange that on 16 July 2026 it executed significant capital-management actions affecting its share base.

• Share cancellation: The company cancelled 14.34 million ordinary shares that had been repurchased between 19 May and 8 July 2026. This cancellation reduced the number of issued shares (excluding treasury shares) by 1.14%, from 1.25 billion to 1.24 billion.

• New buyback: On 16 July 2026 Dingdang Health repurchased an additional 0.20 million shares on the Exchange at prices ranging from HKD 0.90 to HKD 0.92, for a total consideration of HKD 0.18 million. These shares are being held as treasury stock.

• Post-transaction share capital: – Issued shares (excluding treasury shares): 1.24 billion – Treasury shares: 0.88 million – Total issued shares (including treasury shares): 1.24 billion

• Repurchase mandate status: – Authorisation granted on 23 June 2026 allows the company to buy back up to 124.32 million shares. – Cumulative repurchases under the mandate now total 3.74 million shares, equal to 0.30% of the issued share capital on the mandate date. – A 30-day moratorium on issuing new shares or disposing of treasury shares applies until 15 August 2026.

The company confirmed that all transactions complied with Hong Kong listing rules and relevant legal requirements.